Intramyocardial Injection of Mesenchymal Precursor Cells and Weaning From Left Ventricular Assist Device (LVAD) Support
This phase 2 clinical trial investigates whether injecting the myocardium of patients with heart failure with a high dose of mesenchymal precursor cells derived from bone marrow stem cells, compared with a sham injection, repairs myocardial damage enough to facilitate weaning from left ventricular assist devices (LVADs).
Source: JAMA - Category: General Medicine Source Type: research
More News: Cardiology | Clinical Trials | General Medicine | Heart | Heart Failure | Stem Cell Therapy | Stem Cells